For patients and family
What does my MRD blood test result mean?
Last updated November 17, 2026
Not medical advice.
What the test looks for
After cancer treatment, some tests look for tiny pieces of tumor DNA in your blood. Doctors call this ctDNA (circulating tumor DNA). When they use it to check for cancer that may be left after treatment, they call it an MRD test. MRD stands for molecular residual disease.
The test does not count cancer cells. It looks for very small bits of DNA that tumors shed into the blood. The amounts are tiny, often a few pieces in a million or less.
Some MRD tests are built from your own tumor tissue (tumor-informed). Others use only a blood sample (tissue-free or tumor-naive). Both kinds report results in a similar way.
“Undetectable”
An undetectable result means the test did not find tumor DNA in this blood sample.
This is like an HIV or hepatitis C viral-load test that comes back “undetectable.” It means the amount was too low for the test to find, or there was none. It is good news. But it does not prove that every cancer cell is gone. (NIH HIVinfo, checked Nov 17, 2026)
- Some cancers shed very little DNA into the blood. Brain, kidney, prostate and thyroid cancers are examples. With these, a test can miss cancer that is there. (Bettegowda et al., 2014)
- Where cancer comes back also matters. In one colon cancer study, a blood-only test found more returns in the liver (100%) than in the lungs (53%) or the lining of the belly (40%). (Parikh et al., 2024)
That is why doctors often repeat the test over time, along with your usual scans and visits.
“Detected”
A detected result means the test found tumor DNA in this sample. Studies link a detected result after treatment with a higher chance that the cancer will come back. (Tie et al., 2022; Kotani et al., 2023)
A detected result is not a diagnosis that cancer has returned. It is a signal for you and your doctor to look at closely.
- Many reports also give an amount. Over several tests, the trend (going up, going down, or staying low) often tells more than one result.
Results that come and go
Sometimes a test is detected at a very low level, and the next test is undetectable. This can happen with both kinds of tests.
- In a study of 85 people treated for lung cancer, 17 had at least one detected result on a blood-only test. Ten of those 17 later tested undetectable. Eleven of the 17 were positive only at the lowest level the test reports, without any sign of cancer on scans at the time. The three people with clearly higher levels did have cancer come back. The authors said a single low-level result may not need action, and doctors should look at trends. (Cho et al., 2026, Mass General Brigham)
- In a lung cancer study with a tumor-informed test, tumor DNA found in the first 1 to 3 days after surgery did not predict that the cancer would come back. (Gale et al., 2022)
What happens next
This depends on your cancer, your treatment so far, and the test used. Your doctor may:
- repeat the blood test to confirm the result or see the trend
- order a scan or other tests
- talk with you about whether more treatment, a clinical trial, or closer follow-up makes sense
- with an undetectable result, keep your normal follow-up schedule
Do not stop or change any treatment on your own because of an MRD result.
Questions to ask your doctor
The main question: “What will we do differently because of this result?”
Other questions:
- Is this test proven to help with my type and stage of cancer?
- Is my cancer one that sheds a lot or a little DNA into the blood?
- Was this result very low, near the test's limit? Should we repeat it before acting?
- How often will I be tested, and for how long?
- Will Medicare or my insurance pay for it? What will I owe?
Limits of the test
- No test is perfect. It can miss cancer that is there, and it can sometimes find a signal that does not turn into cancer returning.
- Tests differ. Each company measures in its own way and sets its own cutoffs. Results from two different tests are not directly comparable.
- Guidelines are still catching up. The 2026 ASCO guideline says ctDNA testing may be offered when there is a specific, evidence-based action to take with the result, and that the field is changing fast. (Lockwood et al., ASCO Guideline, 2026)
- Coverage is limited. Medicare covers specific tests only for specific cancers and uses. (CMS article A58454, revision effective Oct 1, 2026, checked Nov 17, 2026)
Wording guide for the site (for reviewers)
- Use “undetectable” and “detected.” Avoid “negative/positive” alone and avoid “cancer-free.”
- Do not describe results as numbers of “cancer cells circulating.” The test measures DNA fragments, not cells.
- Do not name a “best” test. Do not imply one result decides treatment.
Sources (all checked Nov 17, 2026)
- NIH HIVinfo, HIV Treatment: The Basics
- Bettegowda C, et al. Sci Transl Med 2014. PMID 24553385. https://pubmed.ncbi.nlm.nih.gov/24553385/
- Parikh AR, et al. Clin Cancer Res 2024. PMID 39110016. https://pubmed.ncbi.nlm.nih.gov/39110016/
- Tie J, et al. N Engl J Med 2022 (DYNAMIC). PMID 35657320. https://pubmed.ncbi.nlm.nih.gov/35657320/
- Kotani D, et al. Nat Med 2023 (GALAXY). PMID 36646802. https://pubmed.ncbi.nlm.nih.gov/36646802/
- Cho JM, et al. JTO Clin Res Rep 2026. PMID 43036776. https://pmc.ncbi.nlm.nih.gov/articles/PMC13770583/
- Gale D, et al. Ann Oncol 2022. PMID 35306155. https://pubmed.ncbi.nlm.nih.gov/35306155/
- Lockwood CM, et al. JCO Oncol Pract 2026 (ASCO guideline). PMID 42314080. https://pubmed.ncbi.nlm.nih.gov/42314080/
- CMS MolDX A58454